This is important, as ovarian tumors are characterized by the presence of cell cycle dysregulation, a hallmark of several types of cancer, [42, 43] and the identification of SLFN5 as a new promoting factor of S phase progression may help expand the currently available armory of cell cycle inhibitors [44, 45]. Here, SLFN5 is linked to ovarian neoplasm.